Effect of buccal dwell time on the pharmacokinetic profile of fentanyl buccal tablet

Expert Opinion on Pharmacotherapy

Volumn 8, Issue 13, 2007, Pages 2011-2016

  Darwish, M ^a   Kirby, M ^a   Jiang, J G ^a  

^a CEPHALON INC   (United States)

Author keywords

Breakthrough pain; Dwell time; Fentanyl buccal tablet; Pharmacokinetics

Indexed keywords

FENTANYL; FENTORA; MYLANTA; PARACETAMOL; UNCLASSIFIED DRUG;

ADULT; ANALGESIA; APPLICATION SITE IRRITATION; APPLICATION SITE PAIN; AREA UNDER THE CURVE; ARTICLE; CHEEK MUCOSA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; DIZZINESS; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG SOLUBILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SHOULDER PAIN; SINGLE DRUG DOSE; TABLET FORMULATION; THORAX PAIN; TIME; VOMITING; BUCCAL DRUG ADMINISTRATION; COMPARATIVE STUDY; DRUG EFFECT; ENTERIC COATED TABLET; HALF LIFE TIME; METABOLISM; METHODOLOGY; MIDDLE AGED; MOUTH MUCOSA; REVIEW;

ADMINISTRATION, BUCCAL; ADULT; FEMALE; FENTANYL; HALF-LIFE; HUMANS; MALE; MIDDLE AGED; MOUTH MUCOSA; RANDOMIZED CONTROLLED TRIALS; TABLETS, ENTERIC-COATED;

EID: 34548605294     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.8.13.2011     Document Type: Article

References (15)

1. STANLEY TH: Fentanyl. J. Pain Symptom Manage. (2005) 29(5 Suppl.):S67-S71.
2. DURFEE S, MESSINA J, KHANKARI R: Fentanyl effervescent buccal tablets. Am. J. Drug Deliv. (2006) 4(1)1-5.
3. PAYNE R: Transdermal fentanyl: suggested recommendations for clinical use. J. Pain Symptom Manage. (1992) 7(3 Suppl.):S40-S44
4. ZEPPETELLA G: Sublingual fentanyl citrate for cancer-related breakthrough pain: a pilot study. Palliat. Med. (2001) 15(4):323-328.
5. REES E: The role of oral transmucosal fentanyl citrate in the management of breakthrough cancer pain. Int. J. Palliat. Nurs. (2002) 8(6):304-308.
6. WEINBERG DS, INTURRISI CE, REIDENBERG B et al.: Sublingual absorption of selected opioid analgesics. Clin. Pharmacol. Ther. (1988) 44(3):335-342.
7. FENTORA® [prescribing information]: Frazer, PA: Cephalon, Inc. (2006).
8. PORTENOY RK, TAYLOR D, MESSINA J, TREMMEL L: A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin. J. Pain. (2006) 22(9):805-811.
9. SLATKIN NE, XIE F, MESSINA J, SEGAL TJ: Fentanyl buccal tablet for relief of breakthrough pain in opioid-tolerant patients with cancer-related chronic pain: a double-blind, randomized, placebo-controlled study. J. Support Oncol. (2007) 5(7):327-334.
10. DARWISH M, TEMPERO K, KIRBY M, THOMPSON J: Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 μg versus oral transmucosal fentanyl citrate 1,600 μg and dose proportionality of FEBT 270 to 1,300 μg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers. Clin. Ther. (2006) 28(5):715-724.
11. DARWISH M, TEMPERO K, KIRBY M, THOMPSON J: Pharmacokinetics and dose proportionality of fentanyl effervescent buccal tablets in healthy volunteers. Clin. Pharmacokinet. (2005) 44(12):1279-1286.
12. 1983 metropolitan height and weight tables. Stat. Bull. Metrop. Life Found. (1983) 64(1):3-9.
13. DARWISH M, KIRBY M, ROBERTSON P Jr, HELLRIEGEL E, JIANG JG: Single-dose and steady-state pharmacokinetics of fentanyl buccal tablet in healthy volunteers. J. Clin. Pharmacol. (2007) 47(1):56-63.
14. DARWISH M, KIRBY M, ROBERTSON P Jr, TRACEWELL W, JIANG JG: Pharmacokinetic properties of fentanyl effervescent buccal tablets: a Phase I, open-label, crossover study of single-dose 100, 200, 400, and 800 μg in healthy adult volunteers. Clin. Ther. (2006) 28(5):707-714.
15. DARWISH M, KIRBY M, ROBERTSON P, HELLRIEGEL E, JIANG JG: Comparison of equivalent doses of fentanyl buccal tablets and arteriovenous differences in fentanyl pharmacokinetics. Clin. Pharmacokinet. (2006) 45(8):843-850.